Why Fighting Back Works

81%

of appealed Medicare Advantage prior authorization denials were overturned in 2024

Source: KFF analysis of Medicare Advantage prior authorization data (January 2026). Covers medical services in Medicare Advantage, not Part D drugs; other plan types differ. Most people never appeal, but most of those who do win.

72 hrs

Max response time for urgent appeals (federal law)

11.5%

Share of Medicare Advantage prior authorization denials that were appealed in 2024 (KFF)

Illustrative Scenarios

These are composite examples based on common denial patterns. They are not stories from Ellen users.

StelaraCrohn's Disease

Patient denied Stelara after insurance required trial of methotrexate first. Filed appeal citing liver disease (elevated ALT/AST) as contraindication to methotrexate, a documented clinical exception.

✓ Approved in 8 days

If you have liver problems, methotrexate step therapy can be bypassed.

DupixentSevere Atopic Dermatitis

Patient denied Dupixent because the prescription came from a primary care doctor. Insurance required a dermatologist or allergist to prescribe.

✓ Approved in 12 days after dermatologist submitted the PA

Many plans require a specialist prescriber for biologics. Ask your doctor for a referral.

OcrevusRelapsing Multiple Sclerosis

Patient denied Ocrevus because insurer required trial of older platform therapy (Copaxone) first. Neurologist submitted peer-to-peer review call citing high disease activity and NCCN guidelines supporting first-line high-efficacy therapy.

✓ Approved after peer-to-peer review in 5 days

Peer-to-peer reviews between your doctor and the insurance medical director overturn denials more often than written appeals alone.

KeytrudaNon-Small Cell Lung Cancer

Patient denied Keytruda because PD-L1 biomarker results were not included in the original PA submission. Oncologist resubmitted with pathology report showing PD-L1 TPS ≥50%.

✓ Approved in 3 days with expedited review

Always include biomarker test results (PD-L1, MSI-H, HER2) with your initial PA submission to avoid delays.

ZofranChemotherapy-Induced Nausea

Patient mid-chemo had their anti-nausea medication suddenly denied after being on it for over a year. Insurance refused to refill, causing severe nausea during active treatment.

✓ Approved after urgent appeal citing active treatment status

If you're denied a supportive care drug during active chemo, request an expedited/urgent appeal, insurers must respond within 72 hours.

NeulastaChemotherapy-Related Neutropenia

Patient denied Neulasta (white blood cell booster) after chemo. Insurer required a lower-cost pegfilgrastim biosimilar (such as Fulphila or Udenyca) first, despite oncologist prescribing Neulasta for dosing convenience.

✓ Patient started the biosimilar after the oncologist agreed it was appropriate

FDA-approved biosimilars have no clinically meaningful differences from the original product. If your doctor agrees, the biosimilar can get you treated faster with fewer insurance fights.

IbranceMetastatic Breast Cancer

Patient denied Ibrance because insurer required genetic testing results confirming HR+/HER2- status. Testing had been done but results weren't included in the PA submission.

✓ Approved in 5 days after resubmission with test results

For targeted cancer therapies, always attach your biomarker/genetic testing results to the initial PA request.

These scenarios are anonymized composites based on common appeal patterns. Individual results vary.

What Patients Are Saying

From a peer-reviewed JAMA study of 89 cancer patients navigating prior authorization.

“The stress of dealing with insurance was worse than the cancer.”

“I was denied life-saving chemotherapy because my insurance company thought it was too expensive. I had to appeal multiple times.”

“Patients should not have to deal with this on top of the stress of a cancer diagnosis, but if patients don't step in and advocate for themselves their treatment will likely fall through the cracks.”

“If I'm a stage 4 cancer patient with an entire team of doctors saying this is what's best, how can an insurance company who doesn't even know me make a choice for me like that.”

Source: JAMA Network Open, 2025